腹膜间皮瘤3例报告

刘晓雯; 钟艳平; 刘培焱; 高沿航

doi:10.3969/j.issn.1001-5256.2019.03.038

腹膜间皮瘤3例报告

DOI: 10.3969/j.issn.1001-5256.2019.03.038

吉林大学第一医院肝胆胰内科

详细信息

中图分类号: R735.5
计量
- 文章访问数: 1310
- HTML全文浏览量: 21
- PDF下载量: 315
- 被引次数: 0
出版历程
- 出版日期: 2019-03-20

Three cases of peritoneal mesothelioma

Department of Hepatology, The First Hospital of Jilin University

摘要

摘要: <正>腹膜间皮瘤为原发于腹膜间皮组织的罕见肿瘤。由于其发病罕见、起病隐匿、临床表现不典型,且尚无特异的血清生化学、影像学辅助检查手段,使得早期诊断颇具挑战性,尤其对于合并其他疾病的患者,更易漏诊。本文对本院收治的3例经活组织病理检查和免疫组化检测确诊腹膜间皮瘤患者的临床资料进行总结,以期提高其早期诊断率,改善预后。
- 间皮瘤 /
- 腹膜肿瘤 /
- 诊断 /
- 治疗学 /
- 病例报告
- mesothelioma /
- peritoneal neoplasms /
- diagnosis /
- therapeutics /
- case reports

HTML全文

参考文献(13)

[1] GUO ZY, CARBONE M, ZHANG X, et al. Improving the accu-racy of mesothelioma diagnosis in China[J]. J Thorac Oncol, 2017, 12 (4) :714-723.

[2] MUNKHOLM-LARSEN S, CAO CQ, YAN TD. Malignant peri-toneal mesothelioma[J]. World J Gastrointest Surg, 2009, 1 (1) :38-48.

[3] RAZA A, HUANG WC, TAKABE K. Advances in the manage-ment of peritoneal mesothelioma[J]. World J Gastroenterol, 2014, 20 (33) :11700-11712.

[4] ARNOLD DT, MASKELL NA. Biomarkers in mesothelioma[J].Ann Clin Biochem, 2018, 55 (1) :49-58.

[5] CLAIMON A, BANG JI, CHEON GJ, et al. Malignant perito-neal mesothelioma masquerades as peritoneal metastasis on (18) F-FDG PET/CT scans; A rare diagnosis that should notbe missed[J]. Nucl Med Mol Imaging, 2015, 49 (4) :325-328.

[6] ALEXANDER HR Jr, BURKE AP. Diagnosis and managementof patients with malignant peritoneal mesothelioma[J]. J Gas-trointest Oncol, 2016, 7 (1) :79-86.

[7] TANDON RT, JIMENEZ-CORTEZ Y, TAUB R, et al. Immuno-histochemistry in peritoneal mesothelioma:A single-centerexperience of 244 cases[J]. Arch Pathol Lab Med, 2018, 142 (2) :236-242.

[8] NAKAMURA K, NAKAYAMA K, NAGAOKA R, et al. The diag-nostic utility of PAX8 immunostaining of malignant peritonealmesothelioma presenting as serous ovarian carcinoma:A sin-gle-center report of two cases[J]. Oncol Lett, 2017, 13 (1) :263-266.

[9] MIRARABSHAHII P, PILLAI K, CHUA TC, et al. Diffuse malig-nant peritoneal mesothelioma-an update on treatment[J].Cancer Treat Rev, 2012, 38 (6) :605-612.

[10] LEE YK, JUN HJ, NAHM JH, et al. Therapeutic strategies forwell-differentiated papillary mesothelioma of the peritoneum[J]. Jpn J Clin Oncol, 2013, 43 (10) :996-1003.

[11] BEEBE-DIMMER JL, FRYZEK JP, YEE CL, et al. Mesothelio-ma in the United States:A Surveillance, Epidemiology, andEnd Results (SEER) -Medicare investigation of treatment pat-terns and overall survival[J]. Clin Epidemiol, 2016, 8:743-750.

[12] PILLAI K, POURGHOLAMI MH, CHUA TC, et al. Prognosticsignificance of Ki67 expression in malignant peritoneal meso-thelioma[J]. Am J Clin Oncol, 2015, 38 (4) :388-394.

[13] LI YC, KHASHAB T, TERHUNE J, et al. Preoperative throm-bocytosis predicts shortened survival in patients with malignantperitoneal mesothelioma undergoing operative cytoreductionand hyperthermic intraperitoneal chemotherapy[J]. Ann SurgOncol, 2017, 24 (8) :2259-2265.

施引文献

资源附件(0)

访问统计